Virtus Fund Advisers’s Puma Biotechnology PBYI Stock Holding History

Virtus Fund Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$955K	Buy	+9,661	New	+$1.08M	0.01%	299
2015 Q3	–	Sell	-8,091	Closed	-$945K	–	856
2015 Q2	$945K	Sell	8,091 -1,983	-20%	-$359K	0.01%	357
2015 Q1	$2.38M	Sell	10,074 -928	-8%	-$198K	0.02%	307
2014 Q4	$2.08M	Buy	11,002 +53	+0.5%	+$11.8K	0.02%	327
2014 Q3	$2.61M	Sell	10,949 -1,905	-15%	-$391K	0.02%	309
2014 Q2	$849K	Buy	+12,854	New	+$914K	0.01%	480

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtus Fund Advisers's PBYI Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Puma Biotechnology (PBYI) in Q4 2017: 9,661 shares worth $955K. The stake represents 0.01% of the portfolio and ranks #299 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in PBYI as recently as Q2 2015.

Virtus Fund Advisers first reported a position in PBYI in Q2 2014 and has held it in 6 quarters since. The position peaked at $2.61M in Q3 2014. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

Virtus Fund Advisers held 9,661 shares of Puma Biotechnology worth $955K as of Q4 2017.
Puma Biotechnology was a new Virtus Fund Advisers position in Q4 2017.
Puma Biotechnology made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #299 holding.
Virtus Fund Advisers first reported a position in Puma Biotechnology in Q2 2014 and has held it in 6 quarters since.
Virtus Fund Advisers's Puma Biotechnology position peaked at $2.61M in Q3 2014.
203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.